{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=11", "query": { "intervention": "Arm 2- Dose Expansion", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:33:19.534Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02988960", "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2017-02-22", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 7, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02988960" }, { "nct_id": "NCT04279847", "title": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome", "Myeloproliferative Neoplasm", "Relapsed or Refractory Primary Myelofibrosis", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "ET (Essential Thrombocythemia)" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2021-02-23", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04279847" }, { "nct_id": "NCT03480646", "title": "ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "CPI-1205", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Constellation Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 175, "start_date": "2017-11-15", "completion_date": "2021-02-03", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 41, "location_summary": "Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480646" }, { "nct_id": "NCT07701941", "title": "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor Positive", "HER2-low or HER2-ultralow", "Unresectable or Metastatic Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2026-09-17", "completion_date": "2032-05-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 12, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07701941" }, { "nct_id": "NCT03881488", "title": "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Mesothelioma", "Melanoma", "Head and Neck Cancer" ], "interventions": [ { "name": "CTX-471", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compass Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2019-05-17", "completion_date": "2025-05-21", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 10, "location_summary": "Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03881488" }, { "nct_id": "NCT04739358", "title": "CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer With MET Mutations" ], "interventions": [ { "name": "Tepotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-05-25", "completion_date": "2023-06-23", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 5, "location_summary": "Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739358" }, { "nct_id": "NCT07397338", "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors", "Non-small Cell Lung Cancer (NSCLC)", "NSCLC", "Colorectal Cancer (CRC)", "CRC" ], "interventions": [ { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Elironrasib", "type": "DRUG" }, { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)", "type": "DRUG" }, { "name": "cetuximab (Cohort C2 Only)", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)", "type": "DRUG" }, { "name": "Daraxonrasib (Cohort B1 only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2026-01-30", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 8, "location_summary": "Los Angeles, California • Norwich, Connecticut • Saint Paul, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397338" }, { "nct_id": "NCT02366949", "title": "Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medical Oncology" ], "interventions": [ { "name": "BAY1217389", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2015-02-27", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 6, "location_summary": "Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02366949" }, { "nct_id": "NCT04748848", "title": "A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid" ], "interventions": [ { "name": "CC-90011", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-10-14", "completion_date": "2022-03-09", "has_results": false, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 11, "location_summary": "Duarte, California • New Haven, Connecticut • Miami, Florida + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04748848" }, { "nct_id": "NCT07047885", "title": "Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Ropeginterferon alfa-2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2025-08-27", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-15T15:33:19.534Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07047885" } ] }